JP2020505465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505465A5 JP2020505465A5 JP2019560493A JP2019560493A JP2020505465A5 JP 2020505465 A5 JP2020505465 A5 JP 2020505465A5 JP 2019560493 A JP2019560493 A JP 2019560493A JP 2019560493 A JP2019560493 A JP 2019560493A JP 2020505465 A5 JP2020505465 A5 JP 2020505465A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 302
- 239000012634 fragment Substances 0.000 claims 70
- 239000000427 antigen Substances 0.000 claims 68
- 102000036639 antigens Human genes 0.000 claims 68
- 108091007433 antigens Proteins 0.000 claims 68
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 239000012528 membrane Substances 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 4
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 claims 3
- 102000051198 human TNFSF14 Human genes 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 claims 2
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000034619 Gingival inflammation Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1701194.1 | 2017-01-24 | ||
| GBGB1701194.1A GB201701194D0 (en) | 2017-01-24 | 2017-01-24 | Antigen binding molecules that bind light |
| PCT/GB2018/050203 WO2018138496A1 (en) | 2017-01-24 | 2018-01-24 | Antigen binding molecules that bind light |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505465A JP2020505465A (ja) | 2020-02-20 |
| JP2020505465A5 true JP2020505465A5 (enExample) | 2021-03-11 |
| JP7140403B2 JP7140403B2 (ja) | 2022-09-21 |
Family
ID=58463068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560493A Active JP7140403B2 (ja) | 2017-01-24 | 2018-01-24 | Ｌｉｇｈｔに結合する抗原結合分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11827673B2 (enExample) |
| EP (1) | EP3574014A1 (enExample) |
| JP (1) | JP7140403B2 (enExample) |
| KR (1) | KR20190110578A (enExample) |
| CN (1) | CN110461875B (enExample) |
| GB (2) | GB201701194D0 (enExample) |
| WO (1) | WO2018138496A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114516913B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测试剂盒 |
| KR20250151071A (ko) | 2024-04-13 | 2025-10-21 | 백수경 | 이동식 방제 박스 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3734795A (en) | 1971-04-23 | 1973-05-22 | Lindsay Wire Weaving Co | Patch and seam for plastic belts |
| US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| AU8755798A (en) | 1997-04-04 | 1998-11-13 | Biosite Diagnostics Incorporated | Polyvalent and polyclonal libraries |
| US7118742B2 (en) | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US6998108B1 (en) | 1997-07-07 | 2006-02-14 | La Jolla Institute For Allergy And Immunology | Antibodies to p30 polypeptides and methods making and using same |
| US6140467A (en) | 1997-07-07 | 2000-10-31 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| DK1674575T3 (da) | 2000-04-12 | 2010-11-29 | Jolla Inst Allergy Immunolog | Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse |
| EP1336619A3 (en) | 2002-02-19 | 2003-12-10 | Millenium Pharmaceuticals, Inc. | Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders |
| CA2481401A1 (en) | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
| EP2484696B1 (en) * | 2006-08-28 | 2017-08-16 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic hLIGHT-specific human monoclonal antibodies |
| UA99714C2 (ru) * | 2006-08-28 | 2012-09-25 | Ля Хойя Інстітьют Фор Еллерджи Енд Іммьюнолоджи | Моноклональное антитело, которое специфически связывается с light |
| US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
| WO2008145142A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| EP2207597B1 (en) | 2007-09-18 | 2020-02-19 | La Jolla Institute for Allergy and Immunology | Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment |
| AU2009308707A1 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
| JP2012521216A (ja) | 2009-03-24 | 2012-09-13 | テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド | Ｌｉｇｈｔに対するヒト化抗体およびその使用 |
| WO2013148350A2 (en) * | 2012-03-26 | 2013-10-03 | Sanofi | Anti-light antibody therapy for inflammatory bowel disease |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| CA3204402A1 (en) | 2012-03-26 | 2013-10-03 | Sanofi | Stable anti-cxcr5 igg4 antibody formulations |
| CA2922375C (en) | 2013-09-06 | 2021-06-15 | Research Development Foundation | Alpha-tea salt forms: compositions and uses for treating disease |
| JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| JP2017504327A (ja) * | 2014-01-14 | 2017-02-09 | カイマブ・リミテッド | 抗ｌｉｇｈｔ抗体 |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| WO2016127059A2 (en) | 2015-02-05 | 2016-08-11 | La Jolla Institute For Allergy And Immunology | Light inhibitors for scleroderma and skin fibrotic disease treatment |
| EP3337509A4 (en) | 2015-08-21 | 2019-01-02 | The Children's Hospital of Philadelphia | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
| US11312781B2 (en) * | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
-
2017
- 2017-01-24 GB GBGB1701194.1A patent/GB201701194D0/en not_active Ceased
-
2018
- 2018-01-24 EP EP18702792.5A patent/EP3574014A1/en active Pending
- 2018-01-24 JP JP2019560493A patent/JP7140403B2/ja active Active
- 2018-01-24 GB GB1820446.1A patent/GB2566389B/en active Active
- 2018-01-24 US US16/480,367 patent/US11827673B2/en active Active
- 2018-01-24 WO PCT/GB2018/050203 patent/WO2018138496A1/en not_active Ceased
- 2018-01-24 KR KR1020197024448A patent/KR20190110578A/ko active Pending
- 2018-01-24 CN CN201880019587.7A patent/CN110461875B/zh active Active
-
2023
- 2023-10-03 US US18/480,379 patent/US20240294655A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| TWI687440B (zh) | Ｓｔ２ｌ拮抗劑及使用方法 | |
| JP2020513791A5 (enExample) | ||
| AU2015322141B2 (en) | High affinity and aggregatively stable antibodies on the basis of variable domains Vl and a derivative VHH | |
| JP2014534218A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| JP2012524071A5 (enExample) | ||
| HRP20170041T1 (hr) | Anti-c5a vezujuće grupe s visokom blokirajućom aktivnošću | |
| JP2010526028A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| CN114144431B (zh) | 人源化抗TNFα抗体及其用途 | |
| JP2011207882A5 (enExample) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2011527899A5 (enExample) | ||
| JP2014519334A5 (enExample) | ||
| JP2016520595A5 (enExample) | ||
| JP2015537190A5 (enExample) | ||
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2024532495A (ja) | 抗ヒトｔｓｌｐモノクローナル抗体及びその使用 | |
| RU2019126888A (ru) | Антитело к человеческому аннексину а1 | |
| RU2014114015A (ru) | Способы лечения воспалительных расстройств с использованием антител против m-csf | |
| JP2012514458A5 (enExample) | ||
| KR20220030934A (ko) | 항-gal9 면역-억제 결합 분자 |